Share this Page:
The results from a phase I/II clinical trial of epacadostat plus pembrolizumab in patients with advanced renal cell carcinoma (RCC) were presented at the American Society of Clinical Oncology (ASCO) Annual Conference in Chicago this week.
Epacadostat is an inhibitor of an enzyme called indoleamine 2,3-dioxygenase (IDO1), and can activate the immune system to destroy cancer cells. Pembrolizumab is an checkpoint inhibitor immunotherapy drug. This phase I/II study included 33 patients with advanced clear cell RCC who received epacadostat and pembrolizumab to determine the safety and efficacy of the combination. The results demonstrate the safety and efficacy of this novel immunotherapy combination of epacadostat with pembrolizumab for patients with advanced RCC who have stopped responding to treatment.
Read more here and the original ASCO abstract here